Literature DB >> 23585983

Two instances of improvement in tardive dyskinesia after administration of aripiprazole in a single patient.

Chih-Lun Chen1, Han-Wei Chou.   

Abstract

Entities:  

Year:  2012        PMID： 23585983      PMCID： PMC3622522          DOI： 10.4088/PCC.11l01315

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN： 2155-7780


× No keyword cloud information.
  10 in total

1.  Aripiprazole-induced improvement in tardive dyskinesia.

Authors:  Harpreet S Duggal
Journal:  Can J Psychiatry       Date:  2003-12       Impact factor: 4.356

2.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

3.  Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.

Authors:  Joseph H Friedman; Robert M Berman; Christopher G Goetz; Stewart A Factor; William G Ondo; Joanne Wojcieszek; William H Carson; Ronald N Marcus
Journal:  Mov Disord       Date:  2006-12       Impact factor: 10.338

4.  Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy.

Authors:  Ali Caykoylu; Okan Ekinci; Elif Yilmaz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-01-23       Impact factor: 5.067

5.  A rating scale for tardive dyskinesia.

Authors:  G M Simpson; J H Lee; B Zoubok; G Gardos
Journal:  Psychopharmacology (Berl)       Date:  1979-08-08       Impact factor: 4.530

6.  Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum.

Authors:  A Inoue; S Miki; M Seto; T Kikuchi; S Morita; H Ueda; Y Misu; Y Nakata
Journal:  Eur J Pharmacol       Date:  1997-02-19       Impact factor: 4.432

Review 7.  Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders.

Authors:  Sanjay Gupta; Prakash Masand
Journal:  Ann Clin Psychiatry       Date:  2004 Jul-Sep       Impact factor: 1.567

Review 8.  Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.

Authors:  J M Kane; J M Smith
Journal:  Arch Gen Psychiatry       Date:  1982-04

Review 9.  Tardive dyskinesia.

Authors:  Karla Soares-Weiser; Hubert H Fernandez
Journal:  Semin Neurol       Date:  2007-04       Impact factor: 3.420

10.  Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.

Authors:  Kevin D Burris; Thaddeus F Molski; Cen Xu; Elaine Ryan; Katsura Tottori; Tetsuro Kikuchi; Frank D Yocca; Perry B Molinoff
Journal:  J Pharmacol Exp Ther       Date:  2002-07       Impact factor: 4.030
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.